Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: cancer

Patients on Dialysis Taking Denosumab May Be at Risk of Severe Hypocalcemia

Michele B. Kaufman, PharmD, BCGP  |  December 12, 2022

The FDA is investigating the risk of severe hypocalcemia with serious outcomes, such as hospitalization and death, in patients on dialysis taking denosumab.

Filed under:Drug Updates Tagged with:denosumabdialysisDrug SafetyFDAhypocalcemiaRenal diseaseU.S. Food and Drug Administration (FDA)

The 2022 ACR Awards of Distinction

Patrice Fusillo  |  December 8, 2022

During ACR Convergence 2022 in early November, the ACR honored a group of individuals who have made significant contributions to rheumatology research, education and patient care by announcing the recipients of the ACR’s 2022 Awards of Distinction, as well as the 2022 ACR Masters, recognized for their contributions to the field. See the November issue…

Filed under:AwardsProfessional Topics Tagged with:Dr. Betty DiamondDr. Cecilia ChungDr. Daniel J. LovellDr. Herbert S. B. BarafDr. J. Michelle KahlenbergDr. James T. RosenbaumDr. Joel M. KremerDr. Judith A. JamesDr. Lisa Criscione-SchreiberDr. Lisa G. RiderDr. Michael D. LockshinDr. Nicolino RupertoDr. Sharad LakhanpalJane Diamond

Highlights from the ACR Review Course 2022

Samantha C. Shapiro, MD  |  December 6, 2022

PHILADELPHIA—At ACR Convergence 2022, the much-anticipated ACR Review Course featured talks from eight experts. Topics reflected the heterogeneity of our field and included Sjögren’s disease, spondyloarthritis (SpA), osteoarthritis (OA), paraneoplastic rheumatic syndromes, metabolic bone disease, statin myopathy, Raynaud’s phenomenon and autoinflammatory syndrome. Here, I share highlights from this comprehensive, six-hour session. Sjögren’s Disease Sara S….

Filed under:ACR ConvergenceConditionsMeeting ReportsOsteoarthritis and Bone DisordersOther Rheumatic ConditionsSjögren’s Disease Tagged with:ACR Convergence 2022ACR Convergence 2022 – ASautoinflammatory diseasemetabolic bone diseaseosteoarthritis (OA)paraneoplastic rheumatic syndromesRaynaud’s phenomenonSjogren'sspondyloarthritis (SpA)statin myopathy

String of Pearls: Lessons in Rheumatoid Arthritis

Jason Liebowitz, MD, FACR  |  December 6, 2022

PHILADELPHIA—William “Bill” R. Palmer, MD, MACR, was the first board-certified rheumatologist in Omaha, Neb., where he spent his entire 43-year clinical career and established himself as a great clinician, mentor and educator. Although Dr. Palmer passed away from metastatic thyroid cancer in August 2021, his memory lives on through his physician colleagues and at ACR…

Filed under:ACR ConvergenceConditionsMeeting ReportsRheumatoid Arthritis Tagged with:ACR Convergence 2022Rheumatoid arthritisRheumatoid Arthritis (RA)

Clinical Rheumatology Year in Review—2022

Samantha C. Shapiro, MD  |  December 4, 2022

In this overview of clinical updates in rheumatology in the last year, high-impact studies were discussed, including the GLORIA, ORAL Surveillance and MIRROR trials.

Filed under:ACR ConvergenceConditionsMeeting ReportsRheumatoid ArthritisSystemic Lupus Erythematosus Tagged with:ACR Convergence 2022COVID-19pegloticaseprednisolone

A Shot of Wisdom: Vaccinations in Patients with Rheumatic Disease

Jason Liebowitz, MD, FACR  |  December 2, 2022

PHILADELPHIA—The treatment of rheumatic diseases is often a double-edged sword: immunosuppressive regimens can be very effective in reducing disease activity, but the cost of such treatments may be seen in the form of increased risk of infection. At ACR Convergence 2022, the session titled ACR Guidelines for Vaccination in Patients with Rheumatic and Musculoskeletal Diseases…

Filed under:ACR ConvergenceClinical Criteria/GuidelinesConditionsMeeting Reports Tagged with:ACR Convergence 2022COVID-19vaccination

Psoriatic Arthritis: Advances in Therapeutics, Imaging & More Presented at ACR Convergence 2022

Walter P. Maksymowych, MB ChB, FACP, FRCP(C)  |  December 1, 2022

PHILADELPHIA—Selecting my top 10 picks for abstracts in psoriatic arthritis (PsA) at the ACR Convergence 2022 meeting was not easy because there was a great deal to review and learn from the 139 abstracts submitted to the meeting. I focused first and foremost on advances in therapeutics that encompassed both new and approved therapeutics, novel…

Filed under:ACR ConvergenceAxial SpondyloarthritisConditionsMeeting ReportsPsoriatic Arthritis Tagged with:ACR Convergence 2022ACR Convergence 2022 – PsAPsoriatic Arthritis

Options for Refractory Gout, ILD & More

Ruth Jessen Hickman, MD  |  November 18, 2022

PHILADELPHIA—At the first Plenary Session of ACR Convergence 2022, on Saturday, Nov. 12, speakers shared key research findings on the efficacy and safety of methotrexate as a co-therapy with pegloticase in refractory gout, the effectiveness of rituximab and cyclophosphamide in connective tissue disease associated-interstitial lung disease and the value of remote education for primary care…

Filed under:ConditionsGout and Crystalline ArthritisOther Rheumatic ConditionsSystemic Sclerosis Tagged with:ACR Convergence 2022ACR Convergence 2022 – Gout

ACR Scores Wins for Rheumatology Community at AMA House of Delegates Interim Meeting

From the College  |  November 17, 2022

Key successes for the rheumatology community secured by the ACR’s delegation include passage of the ACR’s resolution addressing pharmacy benefit administrators, advances in policies to protect rheumatologists and patients in the post-Dobbs landscape and retention of the rheumatology’s representation in the AMA House of Delegates.

Filed under:Legislation & Advocacy Tagged with:ACR advocacyAMA House of Delegates (HOD)third-party pharmacy benefit administrators

Rheumatologist Organizes Medical Mission to Ukraine

Catherine Kolonko  |  November 10, 2022

Early in 2022, a few months into the invasion of Ukraine by Russian troops, Paula Rackoff, MD, a rheumatologist and clinical associate professor at NYU Grossman School of Medicine, New York, felt an urgency to head to the region to assist the many refugees fleeing for the border with Poland. Dr. Rackoff canceled a planned…

Filed under:Professional TopicsProfiles Tagged with:Disaster preparationVolunteering

  • « Previous Page
  • 1
  • …
  • 9
  • 10
  • 11
  • 12
  • 13
  • …
  • 83
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences